Stocks · News reference
NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter
Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
Filed: 2026-10-05 AccNo: 0001213900-26-106677 Size: 232 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
NeuroOne Medical Technologies Announces Southern California Distribution Agreement For OneRF Trigeminal Nerve Ablation System; No Minimum Purchase Commitments
NMTC stock has given up its prior gain. NeuroOne Medical Technologies shares were trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.